Synaptogenix Inc (SNPX)

[SF Wolf]

resident1, fair enough and I should have explained that the study addresses one aspect of the multi-modal effect of treatment with Byrostatin. The reduction of amyloid plaque pathology.

Perhaps the article referenced below that was posted by runncoach on the Investor Village board is more to your point:

Bryostatin-1 Restores Blood Brain Barrier Integrity following Blast-Induced Traumatic Brain Injury

"Bryostatin-1 has been successfully used in numerous animal models of neural injury including TBI, ischemic stroke, auditory neurodegeneration, and Alzheimer’s disease and is currently under investigation in clinical trials...For example, bryostatin-1 protects against loss of pre-synaptic synaptophysin and loss of post-synaptic spinophylin following TBI in mice... Likewise, bryostatin-1 decreased apoptosis and prevented deficits in synaptogenesis in a global model of cerebral ischemia..."

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5000781/